Cancers Of Reproductive System Research Articles

Subsequent primary urogenital cancers among childhood and adolescent cancer survivors in the United States.

To conduct an updated and comprehensive study on the risks of subsequent primary urogenital cancers for childhood and adolescent cancer survivors. This longitudinal study was conducted using 9 cancer registries from the Surveillance, Epidemiology and End Results (SEER) Program with follow-up from 1975 to 2017. There were 43,991 patients diagnosed with first primary cancer from 1975 to 2016 before the age of 20 years who subsequently survived for at least 1 year. Standardized incidence ratios (SIRs) and absolute excess risks (AERs) for urogenital cancers were calculated. Compared with the general population, the risk of urinary system cancer was significantly higher in both female (SIR = 5.18, 95% CI: 3.65-7.14) and male (SIR = 2.80, 95% CI: 1.94-3.92) survivors of any first cancer, with shorter median interval length between first cancer and subsequent urinary system cancer for male survivors (19.9 years) than female survivors (29.3 years). Females also had significantly higher SIR than males for subsequent urinary system cancer (SIRfemale:male=1.86, 95% CI: 1.13-3.03) and kidney cancer (SIRfemale:male = 1.97, 95% CI: 1.11-3.53). Compared with the general population, females with any first cancer had significantly higher risks for cancers of the corpus uteri (SIR = 2.32, 95% CI: 1.49-3.45) and vulva (SIR = 4.27, 95% CI: 1.38-9.95). Childhood and adolescent cancer survivors may have greater female susceptibility for developing subsequent urinary system and kidney cancers, and these survivors may have higher risks for specific types of reproductive system cancers. Our findings may lead to better awareness and surveillance for urogenital cancer by these cancer survivors and their physicians.

Mediterranean Diet as a Shield against Male Infertility and Cancer Risk Induced by Environmental Pollutants: A Focus on Flavonoids.

The role of environmental factors in influencing health status is well documented. Heavy metals, polycyclic aromatic hydrocarbons (PAHs), polychlorinated biphenyls, dioxins, pesticides, ultrafine particles, produced by human activities put a strain on the body’s entire defense system. Therefore, together with public health measures, evidence-based individual resilience measures are necessary to mitigate cancer risk under environmental stress and to prevent reproductive dysfunction and non-communicable diseases; this is especially relevant for workers occupationally exposed to pollutants and/or populations residing in highly polluted areas. The Mediterranean diet is characterized by a high intake of fruits and vegetables rich in flavonoids, that can promote the elimination of pollutants in tissues and fluids and/or mitigate their effects through different mechanisms. In this review, we collected evidence from pre-clinical and clinical studies showing that the impairment of male fertility and gonadal development, as well as cancers of reproductive system, due to the exposure of organic and inorganic pollutants, may be counteracted by flavonoids.

The role of vaccination in the prevention of human papillomavirus (HPV)

Human papillomavirus (HPV) is the most common sexually transmitted infection. This virus affects men and women regardless of age, which leads to the development of various diseases. The article reflects the timely prevention of virus infection in order to avoid serious consequences. HPV causes a wide range of reproductive system cancers, including cervical cancer, vulvar and vaginal cancer, and anal cancer and anogenital warts.

Obesity as a Relative Risk Factor for The Reproductive System Cancer

The article examines the possible effect of metabolites synthesized in adipose tissue on carcinogenesis, in particular in the organs of the reproductive system.

Review On the Effects Curcumin on Tumors of the Reproductive System: Curcumin and Reproductive Tumors.

Curcumin, a polyphenolic derivative of Curcuma longa rhizome, has numerous beneficial effects, including antibacterial, anti-inflammatory, antiviral, antioxidant, antifungal, anti-ischemic, anti-cancer, hypoglycemic, nephroprotective, antirheumatic, hepato-protective, and antimutagenic. Curcumin has indicated the capability to exert anti-cancer activity by multifunctional mechanisms, such as induction of apoptosis, inhibition of cancer cell proliferation, cell cycle regulation, chemotherapeutic intestinal absorption, and modification of several cancer cell types signaling pathways. Several studies have shown that curcumin may have protective effects against tumors of the reproductive system. Reproductive system cancers may cause many undesirable physical and, especially, mental disorders. Infertility and its mental consequences, sexual problems, chemotherapy and surgery-related adverse effects, substantial economic burden, and death are the most common complications regarding the cancers of the reproductive system. By modulating several reproductive cancer hallmarks such as signaling pathways, multiple drug resistance, cancer cell growth and proliferation, tumor angiogenesis, and transcription factors, curcumin could be used as a safe, non-toxic, cheap, and easily accessible drug for treating different types of reproductive cancers.

Review On the Effects of Curcumin on Tumors of the Reproductive System

Curcumin, a polyphenolic derivative of Curcuma longa rhizome, has numerous beneficial effects, including antibacterial, anti-inflammatory, antiviral, antioxidant, antifungal, anti-ischemic, anti-cancer, hypoglycemic, nephroprotective, antirheumatic, hepato-protective, and antimutagenic. Curcumin has indicated the capability to exert anti-cancer activity by multifunctional mechanisms, such as induction of apoptosis, inhibition of cancer cell proliferation, cell cycle regulation, chemotherapeutic intestinal absorption, and modification of several cancer cell types signaling pathways. Several studies have shown that curcumin may have protective effects against tumors of the reproductive system. Reproductive system cancers may cause many undesirable physical and, especially, mental disorders. Infertility and its mental consequences, sexual problems, chemotherapy and surgery-related adverse effects, substantial economic burden, and death are the most common complications regarding the cancers of the reproductive system. By modulating several reproductive cancer hallmarks such as signaling pathways, multiple drug resistance, cancer cell growth and proliferation, tumor angiogenesis, and transcription factors, curcumin could be used as a safe, non-toxic, cheap, and easily accessible drug for treating different types of reproductive cancers. [GMJ.2021;10:e2178]

ETV5-mediated upregulation of lncRNA CTBP1-DT as a ceRNA facilitates HGSOC progression by regulating miR-188-5p/MAP3K3 axis

High-grade serous ovarian cancer (HGSOC) is a common and lethal cancer of the female reproductive system. Long non-coding RNAs (lncRNAs) are aberrantly expressed in various cancers and play crucial roles in tumour progression. However, their function and molecular mechanism in HGSOC remain largely unknown. Based on public databases and bioinformatics analyses, the overexpression of lncRNA CTBP1-DT in HGSOC tissues was detected and validated in a cohort of HGSOC tissues. High expression of lncRNA CTBP1-DT was associated with poor prognosis and was an independent risk factor for survival. Overexpression of lncRNA CTBP1-DT promoted malignant biological behaviour of HGSOC cells, whereas its depletion induced growth arrest of HGSOC cells by vitro and in vivo assays. Mechanistically, lncRNA CTBP1-DT could competitively bind to miR-188-5p to protect MAP3K3 from degradation. Moreover, our results revealed that ETV5 could specifically interact with the promoter of lncRNA CTBP1-DT and activate its transcription. Collectively, these results reveal a novel ETV5/lncRNA CTBP1-DT/miR-188-5p/MAP3K3 pathway for HGSOC progression and suggest that lncRNA CTBP1-DT might be a potential biomarker and therapeutic target for HGSOC.

Precancerous Lesions of the Cervix and Associated Factors among Women of East Gojjam, Northwest Ethiopia, 2020.

BackgroundCervical cancer is the commonest cancer of women’s reproductive system, and is caused by a progression of precancerous lesions of the cervix. Studies on the prevalence and associated factors of precancerous lesions of the cervix are very limited in Ethiopia, particularly in the study area.ObjectiveThis study aimed to assess precancerous lesions of the cervix and associated factors among women of East Gojjam, northwest Ethiopia in 2020.MethodsA facility-based cross-sectional study was conducted on 340 cervical cancer–screened women in three hospitals of East Gojjam from February to April 2020. Data were collected by six BSc-qualified nurses who were working in the selected hospitals. EpiData Manager and SPSS 26 were used for data management and analysis. After the data had been clean, descriptive analysis was done and multivariate logistic regression used to identify predictors of precancerous lesions of the cervix. Statistical significance was taken to be P<0.05.ResultsOf the 340 recruited women, 15.3% (95% CI 11.83%–19.54%) had precancerous cervical lesions. Mean age was 37.11±9.3 years. Age 46–55 (AOR 3.8, 95% CI 1.21–12.47) years, age 56–65 (AOR 12.26, 95% CI 3.18–47.18) years, residing rurally (AOR 2.04, 95% CI 1.12–3.7), prolonged use of oral contraceptive pills (AOR 9.11, 95% CI 1.14–72.8), history of sexual transmitted infection (STI; AOR 3.40, 95% CI 1.32–8.78), HIV-positive status (AOR 4.89, 95% CI 1.54–15.49), and number of lifetime sexual partners (AOR 9.87, 95% CI 1.38–70.4) were important factors associated with precancerous lesions of the cervix.ConclusionWe found relatively high prevalence of precancerous cervical lesions. Age, rural residence, prolonged use of oral contraceptives, STI, multiple sexual partners, and being HIV-positive were important factors associated with precancerous cervical lesions. Women aged >46 years, with a history of STI, being HIV infected, and with a history of multiple sexual partners should be encouraged to get screened for cervical cancer.

Plastic pollution: why is it a public health problem?

Plastic pollution: why is it a public health problem?

PREDICTORS AND PREMORBID CONDITIONS OF THE DEVELOPMENT OF FEMALE GENITAL CANCER, IN PARTICULAR ENDOMETRY CANCER AND BREAST CANCER

Objective: to review a new potential diagnostic criteria for predictors and premorbid conditions of female genital cancer, including endometrial cancer and breast cancer.&#x0D; Materials and methods. Bibliographic, information-analytical methods were used in the work. Sources of information were data from the scientific literature on the topic of the study, modern gadleins, a review of randomized controlled trials.&#x0D; Results. The results of epidemiological studies suggest that the increased risk of cancer of the female reproductive system is the presence of obesity and type 2 diabetes. Potential mechanisms of their association are hyperinsulinemia, hyperglycemia, chronic inflammation, and insulin resistance. Because insulin is a major regulator of cell metabolism and is a tissue growth factor, hyperinsulinemia increases the risk of cancer. Hyperinsulinemia is associated with increased secretion of androgens by the ovaries and decreased levels of the protein that binds sex hormones, leading to higher concentrations of biologically active estrogens, which are also known to be risk factors for female genital cancer. In recent years, PFAA profiles have been found to be significantly altered in cancer and type 2 diabetes. Because cancer cells require certain amino acids to synthesize DNA, tumor growth factors, build new blood vessels, and duplicate all of their protein content, changes in PFAA profiles can be used as biomarkers of disease and different types of cancer at different stages.&#x0D; Conclusions. With the growing incidence of cancer, the issue of early diagnosis and detection of cancer in the pre-clinical stages remains relevant. Protein metabolism in cancer remains unclear and requires further research using a larger sample size. In addition, the biological mechanisms by which amino acids may contribute to the risk and progression of cancer or other premorbid conditions need to be elucidated. Determining the exact mechanism underlying changes in PFAA profiles has great potential for cancer diagnosis and treatment.

Increased risk of malignancy in patients with systemic lupus erythematosus: population-based cohort study in Korea

BackgroundThis study aimed to evaluate the crude incidence rates and relative risk of malignancy in Korean patients with SLE.MethodsWe conducted a retrospective nationwide cohort study using databases from the National Health Insurance Service in Korea. All prevalent SLE patients aged over 19 were identified from January 2012 to December 2014 and observed until the diagnosis of malignancy, death, or end of the study, December 2015. The crude incidence rates (IRs) and standardised incidence ratios (SIRs) of overall and site-specific malignancies in SLE patients were estimated.ResultsWe identified 17,854 SLE patients and during the observation period (60,511 person-years [PYs]), 768 solid malignancies (126.9/10,000 PYs) and 68 haematologic malignancies (11.2/10,000 PYs) occurred in SLE patients. In SLE patients, breast and reproductive system and thyroid cancers occurred predominantly, followed by liver and colon cancers. The SIRs of overall, solid, and haematologic malignancies of SLE patients compared to the general population were 1.8 (95% confidence interval [CI] 1.6–1.9), 1.7 (95% CI 1.5–1.8), and 5.9 (95% CI 4.8–7.3), respectively. In solid malignancies, head and neck (2.7, 95% CI 1.1–4.2), bladder (2.4, 95% CI 1.1–3.8), liver (1.9, 95% CI 1.4–2.3), pancreas (1.9, 95% CI 1.3–2.6), lung (1.8, 95% CI 1.2–2.4), colon (1.7, 95% CI 1.3–2.2), thyroid (1.6, 95% CI 1.3–1.8) and breast and reproductive system (1.5, 95% CI 1.2–1.7) cancers are at increased risk in SLE patients.ConclusionAn increased risk of haematologic and solid malignancies was observed in Korean patients with SLE compared to the general population.

Association Between Metabolic Syndrome and Risk of Endometrial Cancer

Background: Endometrial cancer is one of the most common cancers of the female reproductive system, and it is one of the rise globally. metabolic syndrome is a clustering of at least three of the five following medical conditions: central obesity, diabetes, hypertension, high serum triglyceride and low serum high density lipoprotein. Aim: The aim of this study was to assess the association between the metabolic syndrome and the endometrial cancer. Methods: this case control study comprised of 93 patients with abnormal uterine bleeding admitted to department of obstetrics and gynecology, Tishreen University Hospital, Lattakia Syria, during the period of February 2019 To February 2021, patients who full field the inclusion criteria for the study were divided into 2 groups, the first consisted of 31 patients had endometrial cancer with histological confirmation (cases). The second consisted of 62 patients with normal biopsies (controls). The determination of the metabolic syndrome is according to NCEP ATP III(2005) Results: Baseline characteristics were matched in both study groups. In assessment the association between the metabolic syndrome and the endometrial cancer the odd ratio (OR) was (3.31). the odd ratio (OR) for metabolic syndrome (MS) elements were (2.9 with diabetes, 3.9 with obesity, 2.05 with hypertension, 2.36 with high triglyceride and 1.2 with low high density lipoprotein). Conclusion: the metabolic syndrome and its elements are causes of endometrial cancer.

Work with cancer or stop working after diagnosis? Variables affecting the decision.

Studies about work and cancer predominantly considered the return to work of cancer survivors. However, some studies highlighted that many patients work with cancer even immediately after the diagnosis. Little is known about the frequency, causes, and consequences of this behavior. This study aimed to estimate how many cancer patients continue working in the month after the diagnosis in an Italian context and to determine which factors affect the decision to stop working in the same period. One hundred seventy-six patients with breast, gastrointestinal, prostate, or female reproductive system cancer completed a survey with demographic, occupational, and psychosocial information. Clinical information was collected from medical records. We measured how many workers continued working in the month after cancer diagnosis without substantial interruptions and selected the best logistic regression model of this behavior's predictors. Sixty-eight percent of the patients continued working in the month after the diagnosis. Patients were more likely to stop working with a higher level of perceived work-health incompatibility (OR = 2.64; 95%CI: 1.48-4.69), an open-ended contract (OR = 3.20; CI: 1.13-9.09), and a complex treatment (surgery+chemo-/radio-therapy, OR = 4.25; CI: 1.55-11.65) and less likely with breast cancer (OR = 0.20; CI: 0.07-0.56), and more children (OR = 0.59; CI: 0.37-0.96). To continue working with cancer is a common practice among the newly diagnosed. The decision to suspend work activity relates to evaluating how much work activities hamper one's health care needs and the practical difficulties expected in handling cancer care and work.

World Trade Center Health Program - United States, 2012-2020.

Problem/ConditionAfter the September 11, 2001, terrorist attacks on the United States, approximately 400,000 persons were exposed to toxic contaminants and other factors that increased their risk for certain physical and mental health conditions. Shortly thereafter, both federal and nonfederal funds were provided to support various postdisaster activities, including medical monitoring and treatment. In 2011, as authorized by the James Zadroga 9/11 Health and Compensation Act of 2010, the CDC World Trade Center (WTC) Health Program began providing medical screening, monitoring, and treatment of 9/11-related health conditions for WTC responders (i.e., persons who were involved in rescue, response, recovery, cleanup, and related support activities after the September 11, 2001, terrorist attacks) and affected WTC survivors (i.e., persons who were present in the dust or dust cloud on 9/11 or who worked, lived, or attended school, child care centers, or adult day care centers in the New York City disaster area).Reporting Period Covered2012–2020.Description of SystemThe U.S. Department of Health and Human Services WTC Health Program is administered by the director of CDC’s National Institute for Occupational Safety and Health. The WTC Health Program uses a multilayer administrative claims system to process members’ authorized program health benefits. Administrative claims data are primarily generated by clinical providers in New York and New Jersey at the Clinical Centers of Excellence and outside those states by clinical providers in the Nationwide Provider Network. This report describes WTC Health Program trends for selected indicators during 2012–2020.ResultsIn 2020, a total of 104,223 members were enrolled in the WTC Health Program, of which 73.4% (n = 76,543) were responders and 26.6% (n = 27,680) were survivors. WTC Health Program members are predominantly male (78.5%). The median age of members was 51 years (interquartile range [IQR]: 44−57) in 2012 and 59 years (IQR: 52−66) in 2020. During 2012−2020, enrollment and number of certifications of WTC-related health conditions increased among members, with the greatest changes observed among survivors. Overall, at enrollment, most WTC Health Program members lived in New York (71.7%), New Jersey (9.3%), and Florida (5.7%). In 2020, the total numbers of cancer and noncancer WTC-related certifications among members were 20,612 and 50,611, respectively. Skin cancer, male genital system cancers, and in situ neoplasms (e.g., skin and breast) are the most common WTC-related certified cancer conditions. The most commonly certified noncancer conditions are in the aerodigestive and mental health categories. The average number of WTC-related certified conditions per certified member is 2.7. In 2020, a total of 40,666 WTC Health Program members received annual monitoring and screening examinations (with an annual average per calendar year of 35,245). In 2020, the total number of WTC Health Program members who received treatment was 41,387 (with an annual average per calendar year of 32,458).InterpretationSince 2011, the WTC Health Program has provided health care for a limited number of 9/11-related health conditions both for responders and survivors of the terrorist attacks. Over the study period, program enrollment and WTC certification increased, particularly among survivors. As the members age, increased use of health services and costs within the WTC Health Program are expected; chronic diseases, comorbidities, and other health-related conditions unrelated to WTC exposures are more common in older populations, which might complicate the clinical management of WTC-related health conditions.Public Health ActionAnalysis of administrative claims data in the context of WTC research findings can better clarify the health care use patterns of WTC Health Program members. This information guides programmatic decision-making and might also help guide future disaster preparedness and response health care efforts. Strengthening the WTC Health Program health informatics infrastructure is warranted for timely programmatic and research decision-making.

In vitro anticancer activity of ethanol extract of Adhatoda vasica Nees on human ovarian cancer cell lines

BackgroundOvarian cancer causes more deaths than any other cancer of the female reproductive system because there is no effective screening and most women are diagnosed at advanced stages. The probability of survival at 5 years is less than 30%, and the limitation is that it will not respond to chemotherapy protocol and surgery as well. Moreover, some evidence have shown potential anticancer properties of flavonoids, protective chemicals in plant foods, such as being an antioxidant, antiestrogenic, antiproliferative, and antiinflammatory. In this study, the anticancer activity of crude ethanol extracts of leaves from Adhatoda vasica was investigated. ResultsBy the application of a cell-based assay, the LC 50 value of the A. vasica which showed anticancer effect was used for further studies. The cell line treated with LD 50 value of A. vasica extracts was observed for 0 h, 24 h, and 48 h to reveal the inhibition of the metastatic property in treated PA1 cells. The mRNA isolated from the teratocarcinoma PA1 cells treated with the A. vasica extract was further converted to cDNA and was amplified for the analysis of the p53 gene, p21 gene, and GAPDH gene expression. The expression in treated cells and the untreated control indicated the activity of the A. vasica extract against the ovarian cancer. ConclusionThe present study suggested the antiproliferative and antimetastatic effects of medicinal plant A. vasica on PA1 cells.

Risk Factors and Quality of life among Saudi Woman with Reproductive System Cancer

Reproductive cancers have a huge impact in woman quality of life. Research on Saudi Arabian cancer patients is a priority at King Abdulaziz Medical City (KAMC), Riyadh. To date, research on quality of life in cancer patients in Saudi Arabia has been insufficient and there is no enough research that assesses quality of life in gynecological cancer in Saudi women. The aims of this study were to assess the gynecological cancer risk factors and measure the quality of life among Saudi woman who diagnosed with uterine, ovarian or cervical cancer. A descriptive cross-sectional correlational design was used to conduct the study. A convenient sample of 100 Saudi women and who diagnosed with one of reproductive cancer type at King Abdullah Specialized Children Hospital, Riyadh city. Each woman in the sample signed an informed consent to participate in the study. Data was collected using risk factors assessment tool and WHOQOL-BREF questionnaire. Validly and reliability of the questionnaire were ensured. The mean age of the sample was 49.01 ± 12.88 years, 57 % got menarche at age 13 years, 25% had family history of gynecological cancer, 45% had gotten recurrent genital tract infections, and 47% had an abnormal Pap smear results. There was a statistically significant relationship between the physical health domain and social status (p=0.003), occupation (p=0.000) and monthly income (p=0.040). However, woman psychological health domain was significantly related to occupation n (p=0.000), number of abortions (p=0.001) and menstrual age (p=0.034). It was clear that the age (p=0.024), social status (p=0.011) educational level (p=0.023), and reproductive system hygiene (p=0.005) had significant relationship with woman social relationships domain. Half of the sample had good total quality of life score &gt;70%, while only 11% had poor total quality of life score &lt;50%. This study presented substantial findings that the sample had a moderate quality of life.

Radioproteomics in patients with ovarian cancer.

Radioproteomics is the integration of proteomics, the systematic study of the protein expression of an organism, with radiomics, the extraction and analysis of large numbers of quantitative features from medical images. This article examines this developing field, and it's application in high grade serous ovarian carcinoma. Seminal proteomic studies in the area of ovarian cancer, such as the PROVAR and CPTA studies are discussed, along side recent research, such as that highlighting the central role of methyltransferase nicotinamide N-methyltransferase as the metabolic regulation of cancer progression in the tumour stroma. Finally, this article considers a novel, hypothesis generating approach to integrate CT-based qualitative and radiomic features with proteomic analysis, and the future direction of the field. Combined advances in radiomic, proteomic and genomic analysis has the potential to signal the age of true precision medicine, where treatment is centered specifically on the molecular profile of the tumour, rather than based on empirical knowledge, thus altering the course of a disease that has the highest mortality of all cancers of the female reproductive system.

Bevacizumab (Avegra®) for the treatment of gynecological cancers: joint experience of several centers

Tumors of the female reproductive system are among the five most common cancers in women worldwide. Up to 60 % of these patients require chemotherapy to reduce the risk of recurrence. Currently, an additional treatment option is available for patients with advanced cancers of the female reproductive system, namely vascular endothelial growth factor inhibitor bevacizumab. To assess the efficacy and safety of Avegra®, Russian generic of bevacizumab, we summarized the experience of 5 specialized healthcare institutions that used it for the treatment of 178 patients with tumors of the female reproductive system. The analysis of side effects in 1,074 treatment cycles demonstrated that Avegra® had a good safety profile. Clinical effects of Avegra® were similar to those of the original drug.

Bisphenol A induces ovarian cancer cell proliferation and metastasis through estrogen receptor-α pathways.

Bisphenol A (BPA) is a widely used raw material that can be detected both in the environment and in the human body. Due to its estrogen-like effects, wide concerns have been raised about the potential role of BPA in the initiation and development of hormone-dependent cancers. Ovarian cancer is the most common reproductive system cancer and has a high mortality rate in women. Despite recent investigations into BPA's carcinogenic effects, studies on its role in ovarian cancer development remain limited. In this study, we aimed to assess the effect of BPA at various environmentally relevant concentrations on proliferation and metastasis of ovarian cancer cells. We discovered that BPA can stimulate proliferation of OVCAR-3 ovarian cancer cells after exposure for up to 5 days. Strikingly, BPA enhanced ovarian cancer cell migration, invasion, and adhesion (to vascular endothelial cells) through upregulation of matrix metalloproteinase-2 (MMP-2), MMP-9, and intercellular cell adhesion molecule-1 (IMAC-1). The stimulatory effects of BPA on cancer cell proliferation and metastasis were reversed by treatment with an ERα inhibitor, but not by treatment with an ERβ inhibitor. Together, these results suggest that BPA induces proliferation and metastasis of ovarian cancer cells through ERα signaling pathways. This study provides new insights into the carcinogenic effects of BPA with regard to ovarian cancer.

Opportunities for robotic-assisted surgery in treatment of uterine cancer. Current view on the problem

Endometrial cancer holdzone of the lead positions in the pattern of female oncological diseases, affecting annually around 300,000 women worldwide. Compared to other cancers of the female reproductive system, this pathology has been extensively investigated by conducting large-scale randomized controlled trials, which proved safety and efficacy of using laparoscopic surgery for such patients. In the last years, robotic-assisted surgery has been actively developed globally, including gynecological oncology. Minimally invasive technologies can reduce the volume of blood loss, shorten hospital stay, lower rate of postoperative complications and shorten rehabilitation period. It is necessary to conduct randomized prospective studies assessing robotic-assisted surgery for treating endometrial cancer, especially due to concerns about postoperative prognosis in cancer patients. In addition, studies on developing clinical guidelines to select proper surgical intervention, including robotic-assisted access for surgeons-oncologists are required.